Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
Julian Elliott(Durham University), Sharon R. Lewin(Peter Doherty Institute), Rebecca Hoh(University of California, San Francisco), Wendy Hartogensis(University of California, San Francisco), Janine Roney(Monash University), Namandjé N. Bumpus(Johns Hopkins University), Peter Bacchetti(University of California, San Francisco), Steven G. Deeks(University of California, San Francisco), Sulggi A. Lee(San Francisco General Hospital), Christina C. Chang(The University of Melbourne), James McMahon, Michael Piatak, Ajantha Solomon(The Royal Melbourne Hospital), Jeff Lifson(Leidos (United States)), Rada Savic(University of California, San Francisco), Robert J. Gorelick(Frederick National Laboratory for Cancer Research)
Cited by 248
Related Papers
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
|Nature Medicine|2006|3.6k
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival
|Hepatology|2001|2.3k
Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection
|The Journal of Infectious Diseases|2011|1.1k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k